Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
E MaquoiA Noel

Abstract

The implication of matrix metalloproteinases (MMPs) in the major stages of cancer progression has fueled interest in the design of synthetic MMP inhibitors (MMPIs) as a novel anticancer therapy. Thus far, drugs used in clinical trials are broad-spectrum MMPIs the therapeutic index of which proved disappointingly low. The development of selective MMPIs for tumor progression-associated MMPs is, thus, likely to offer improved therapeutic possibilities. The anti-invasive capacity of a series of pyrimidine-trione derivatives was tested in vitro in a chemoinvasion assay, and the most potent compound was further evaluated in vivo in different human tumor xenograft models. The activity of this novel selective MMPI was compared with BB-94, a broad-spectrum inhibitor. Ro-28-2653, an inhibitor with high selectivity for MMP-2, MMP-9, and membrane type 1 (MT1)-MMP, showed the highest anti-invasive activity in vitro. In vivo, Ro-28-2653 reduced the growth of tumors induced by the inoculation of different cell lines producing MMPs and inhibited the tumor-promoting effect of fibroblasts on breast adenocarcinoma cells. Furthermore, Ro-28-2653 reduced tumor vascularization and blocked angiogenesis in a rat aortic ring assay. In contrast, BB-94 u...Continue Reading

References

Jan 1, 1988·Advances in Cancer Research·A van den Hooff
Oct 1, 1994·Pathology, Research and Practice·A NoëlJ M Foidart
Jan 1, 1997·Investigational New Drugs·S M Wojtowicz-PragaM J Hawkins
Apr 16, 1998·International Journal of Cancer. Journal International Du Cancer·A NoëlJ M Foidart
Oct 13, 1998·The Journal of Bone and Joint Surgery. British Volume·J W HutchinsonT R Davis
Jul 23, 1999·Annals of the New York Academy of Sciences·A H DrummondA Wright
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A R NelsonL M Matrisian
Mar 29, 2000·Proceedings of the National Academy of Sciences of the United States of America·Z ZhouK Tryggvason
Oct 12, 2000·Nature Cell Biology·G BergersD Hanahan
Feb 7, 2001·Journal of the National Cancer Institute·M Hidalgo, S G Eckhardt
Nov 1, 2001·Annual Review of Cell and Developmental Biology·M D Sternlicht, Z Werb
Jan 25, 2002·Angiogenesis·S BlacherJ M Foidart
Mar 29, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N E SounniA Noel
Mar 30, 2002·Science·Lisa M CoussensLynn M Matrisian
May 7, 2002·Nature Reviews. Cancer·Mikala Egeblad, Zena Werb
Aug 8, 2002·Journal of the National Cancer Institute·Suyun HuangIsaiah J Fidler
Sep 5, 2002·Nature Reviews. Cancer·Christopher Mark Overall, Carlos López-Otín
Apr 3, 2003·International Journal of Cancer. Journal International Du Cancer·Christèle BissonAgnès Noel
Apr 26, 2003·Matrix Biology : Journal of the International Society for Matrix Biology·N E SounniA Noel
Jun 5, 2003·Expert Opinion on Therapeutic Targets·Barbara Fingleton
Jun 10, 2003·Arthritis and Rheumatism·Richard RenkiewiczVijaykumar Baragi
Oct 1, 2003·Nature Genetics·Milagros BalbínCarlos López-Otín

❮ Previous
Next ❯

Citations

Jul 31, 2007·Cancer Immunology, Immunotherapy : CII·Valeska HofmeisterJürgen C Becker
May 9, 2006·Cancer Metastasis Reviews·Jed F Fisher, Shahriar Mobashery
Oct 31, 2007·Clinical & Experimental Metastasis·Vincent Chabottaux, Agnès Noel
Apr 2, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Haoqian ZhangLinda J Noble-Haeusslein
Jan 10, 2006·Cancer Biotherapy & Radiopharmaceuticals·Ruth OltenfreiterGuido Slegers
Apr 13, 2012·American Journal of Physiology. Endocrinology and Metabolism·Zongzhi YinRaouf A Khalil
Apr 23, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·E HadjipanayiA F Schilling
Jul 12, 2011·Cellular and Molecular Life Sciences : CMLS·Hui HuaYangfu Jiang
Nov 22, 2011·Molecular Aspects of Medicine·Diego SbardellaMassimo Coletta
Aug 25, 2015·Neoplasia : an International Journal for Oncology Research·Oriane CarnetAgnès Noel
Aug 7, 2007·Biochemical Pharmacology·Joseph D Raffetto, Raouf A Khalil
Feb 22, 2005·Biochemical and Biophysical Research Communications·Diego DemeulemeesterH Roger Lijnen
Mar 23, 2005·Biochimie·N E Sounni, A Noel
Oct 4, 2006·Free Radical Biology & Medicine·Ping PeiSusan R Mallery
Apr 4, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Shu-Chih LiuYih-Shou Hsieh
Apr 22, 2008·Nature Methods·Françoise BruyèreAgnès Noël
Aug 12, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ali Mohammad AlizadehSadaf Farsinejad
Aug 29, 2009·Biochimica Et Biophysica Acta·Jennifer A JacobsenSeth M Cohen
Nov 15, 2011·Bioorganic & Medicinal Chemistry·Claudia BelloPierre Vogel
Nov 8, 2014·Nature Reviews. Drug Discovery·Roosmarijn E Vandenbroucke, Claude Libert
Feb 6, 2019·Chemistry : a European Journal·Thomas FischerRainer Riedl
Sep 10, 2020·MedChemComm·Geetha B KumarDavid B C Martin
Jun 7, 2017·Journal of Cellular Biochemistry·Evette S RadiskyDerek C Radisky
Mar 29, 2018·Current Medicinal Chemistry·Linda CerofoliniClaudio Luchinat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.